Pricing
  1. JP-listed companies
  2. Ina Research Inc.
  3. Financials
  4. Total non-current liabilities

Ina Research Inc. (E20922)

Market cap
P/E ratio
Inari Research provides contract testing services to help pharmaceutical companies evaluate drug safety and effectiveness using GLP-compliant laboratory facilities.
SummaryFinancialsDividendsHistoryWorkforce
Period EndTotal non-current liabilities (Million JPY)YoY (%)
Mar 31, 2022819-15.15%
Mar 31, 2021965-6.12%
Mar 31, 20201,028-0.79%
Mar 31, 20191,037+42.82%
Mar 31, 2018726-0.54%
Mar 31, 2017730-23.11%
Mar 31, 2016949+47.15%
Mar 31, 2015645-17.94%
Mar 31, 2014786-4.44%
Mar 31, 2013823

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat